ARQ-092 is primarily utilized in the field of oncology as a targeted therapy for various types of cancers. It functions as an AKT inhibitor, which plays a crucial role in the PI3K/AKT/mTOR signaling pathway, often dysregulated in cancer cells. By inhibiting AKT, ARQ-092 helps to suppress tumor growth and proliferation, making it a potential treatment option for cancers such as breast, ovarian, and prostate cancer. Additionally, it is being investigated for its efficacy in treating Proteus syndrome, a rare genetic disorder characterized by overgrowth of tissues, due to its ability to modulate the AKT pathway. Its application in clinical trials has shown promise in improving patient outcomes by targeting specific molecular pathways involved in disease progression.